Online Pharmacy Training

HARVONI   It is a combination of ledipasvir (90mg), a (HCV) NS5A inhibitor, and sofosbuvir (400mg), an HCV nucleotide analog NS5B polymerase inhibitor. HARVONI was approved by FDA on 10  October  2014, as first Hepatitis C drug combination, that used alone without need to ribavirin or peginterferon alfa, as in case of SOVALDI. Harvoni 15 facts: Used for treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. HARVONI dose is one tablet to be taken once daily regardless of food. Treatment duration varies according to the case and presence of liver cirrhosis. In naive cirrhotic or not, and in experienced non cirrhotic, they treated for 12 weeks. In naive non-cirrhotic patient with PCR < 6million IU/ml, treatment may reduced to 8 weeks. In experienced cirrhotic patients the treatment extends for 24 weeks. Experienced patients who have failed to treat with other medications. HARVONI used alone without the need to peginterferon al...

Management of mechanical heart valves in pregnancy is still a clinical dilemma for women and clinician, because of pregnancy itself considers pro thrombotic state and the options available for management of this case still Subject to benefit risk choice.

U.S. Food and Drug Administration (FDA) has approved the dermal filler, Bellafill- polymethylmethacrylate (PMMA) collagen filler - for the treatment of skin condition scars. Bellafill represents a big clinical advancement because the solely filler on the market approved for this disfiguring skin condition. skin condition is that the commonest skin condition within the U.S., poignant 40-50 million people1 and up to ninety fifth of individuals with skin condition could endure to suffer from scarring.  Bellafill was studied extensively before its office approval and established to be safe and effective for the correction of moderate to severe, atrophic, expansive facial skin condition scars on the cheek in patients over the age of twenty one years.

FDA approved Lynparza for treatment of Advanced Ovarian Cancer The U.S. Food and Drug Administration nowadays granted accelerated approval to Lynparza (olaparib), a brand new drug treatment for ladies with advanced ovarian cancer related to defective BRCA genes, as detected by associate degree FDA-approved take a look at. Ovarian cancer forms within the ovary, one in all a try of feminine reproductive glands wherever ova, or eggs, are formed. The National Cancer Institute estimates that 21,980 american girls are going to be diagnosed with and 14,270 can die from ovarian cancer in 2014. Lynparza is a poly ADP-ribose enzyme (PARP) substance that blocks enzymes concerned in repairing broken DNA. it's meant for ladies with heavily pretreated gonad cancer that's related to defective BRCA genes. “Today’s approval constitutes the primary of a brand new category of medication for treating gonad cancer,” same Richard Pazdur, MD, director of the workplace of haematology and medicin...

Noradrenaline  -  norepinephrine Drug name Sympathomimetic   (Vasopressor) Group Stimulates alpha-receptors in arterial and venous beds and beta 1 receptors of heart, resulting in peripheral vasoconstriction and stimulation of heart rate and contractility. Coronary vasodilation occurs secondary to enhanced myocardial contractility. Mechanism of action duration Interval dose Uses Cont. infusion 0.01–0.4 µg/kg/min IV infusion via a central vein           Septic shock ,with low SVR Severe hypertension may occur if noradrenaline is given to patients taking tricyclic antidepressants since tricyclics block the uptake of noradrenaline into nerve endings. Drug interaction Bradycardia Hypertension Arrhythmias Myocardial ischaemia peripheral ischaemia Side effects Hypovolaemic ...

Ph D: Neven Mohamed For many years, calcium-containing phosphate binders (calcium acetate and calcium carbonate) were considered the best choice in the treatment of hyperphosphatemia, due to they are effective, possessed only moderate side-effects and suppressed parathormone levels with the intention of counteracting progression of secondary hyperparathyroidism. In two head-to-head observational studies (CARE, ARNOS), calcium-containing binders showed signals of clinical superiority versus the comparator sevelamer-HCl. [1.2]   Nevertheless, calcium may be absorbed significantly, which may result in a positive calcium balance and actively contribute progressive cardiovascular and soft-tissue calcification in patients at risk. [3]

The US Food and Drug Administration ( FDA ) has approved Natesto (testosterone),  once  CompleoTRT™,  the primary  and  solely  androgen  nasal gel for replacement  medical aid  in adult males for conditions  related to  a deficiency or absence of endogenous  androgen . Natesto is self-administered via a nasal  applier  thereby minimizing  the chance  of secondary exposure to  androgen   of girls  or  youngsters .

1 Abilify aripiprazole   Otsuka $6,460,215,394 2 Nexium esomeprazole   AstraZeneca $6,135,667,614 3 Humira adalimumab AbbVie $5,549,996,855 4 Crestor   rosuvastatin AstraZeneca $5,310,818,889 5 Cymbalta duloxetine Eli Lilly $5,219,860,418 6 Advair Diskus fluticasone propionate/salmeterol GlaxoSmithKline $5,121,312,668 7 Enbrel etanercept Amgen $4,681,201,645 8 Remicade infliximab Centocor $4,098,233,242 9 Copaxone glatiramer acetate Teva Pharm $3,697,182,238 10 Neulasta pegfilgrastim Amgen $3,580,364,758

The U.S. Food and Drug Administration today announced it is requiring the removal of certain restrictions on prescribing and use of the diabetes drug Avandia (rosiglitazone) to reflect new information regarding the cardiovascular risk of the medicine. Today’s actions are consistent with the recommendations of expert advisory committees. Results from the Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes (RECORD) clinical trial showed no elevated risk of heart attack or death in patients being treated with Avandia when compared to standard-of-care diabetes drugs. These data do not confirm the signal of increased risk of heart attacks that was found in a meta-analysis of clinical trials first reported in 2007. In addition to Avandia, rosiglitazone is available in combination with other diabetes medications, including metformin under the brand name Avandamet and glimepiride under the brand name Avandaryl.  http://www.fda.go...

THURSDAY May 16, 2013 -- An experimental drug that taps the power of the body's immune system to fight cancer is shrinking tumors in patients for whom other treatments have failed, an early study shows.

TUESDAY March 19, 2013 --  People who take high doses of popular cholesterol-lowering drugs called statins may be more likely to develop kidney problems, a new study suggests. Specifically, those participants who took higher doses of statins were 34 percent more likely to be hospitalized for acute kidney injury during the first 120 days of treatment, compared to their counterparts who were taking lower doses. This risk remained elevated two years after starting treatment. The findings appeared online March 19 in the journal  BMJ .

FRIDAY, January 20, 2012 - The U.S. Food and Drug Administration today approved Zetonna (ciclesonide) nasal aerosol to treat the symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.

The US Food and Drug Administration has approved Subsys (fentanyl) sublingual spray. Subsys is a sublingually-administered formulation of fentanyl which provides relief to patients who experience episodes of breakthrough cancer pain. Breakthrough cancer pain is characterized by sudden, often unpredictable, episodes of intense pain which can peak in severity at three to five minutes despite background pain medication. Subsys is approved in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

The U.S. Food and Drug Administration (FDA) has approved Anturol (oxybutynin) topical gel 3% for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.

The U.S. Food and Drug Administration has approved Intermezzo (zolpidem tartrate sublingual tablets) for use as needed to treat insomnia characterized by middle-of-the-night waking followed by difficulty returning to sleep.

The U.S. Food and Drug Administration (FDA) has approved Eylea (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams (mg) every four weeks (monthly) for the first 12 weeks, followed by 2 mg every eight weeks (2 months).

Clinical Context Tadalafil is a phosphodiesterase-5 (PDE5) inhibitor that was approved by the US Food and Drug Administration (FDA) in 2003 to treat erectile dysfunction (ED). The FDA has now expanded the approved indications to include benign prostatic hyperplasia (BPH), either alone or in combination with ED.

The U.S. Food and Drug Administration (FDA) has approved Onfi (clobazam), an oral benzodiazepine antiepileptic drug, as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients two years and older.

October 14, 2011 -- The U.S. Food and Drug Administration today approved Ferriprox (deferiprone) to treat patients with iron overload due to blood transfusions in patients with thalassemia, a genetic blood disorder that causes anemia, who had an inadequate response to prior chelation therapy.

Although not a complete list, below you’ll find a list of the most common medications that require refrigeration.     * • Actimmune® (interferon gamma 1B)     * • Benzamycin® (erythromycin/benzoyl peroxide)--gel     * • Benzaclin® (clindamycin/benzoyl peroxide)--gel     * • Betaseron® (interferon beta 1B)--vials